The Janssen results aren't far off either; Q3 of this FY so we have news scheduled for some time in Jan to Mar 2020. If things go well our revenue pipeline will be fasttracked and no doubt the SP will rerate. In the mean time there are a number of positive developments that can pop up at any time like a US distribution partner, and the ramping of revenue from the current licensees. Guardia is a wildcard, I think there's more there than they are telling us. Why suspend endometriosis and not guardia? Would have thought Endometriosis to be the more important from a market perspective so I'm thinking that validation for Guardia is all but a foregone conclusion... or am I just contra-conspiracy nutjob?
PIQ Price at posting:
32.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)